BAD HOMBURG, Germany--(BUSINESS WIRE)--July 20, 2006--Fresenius Medical Care (“the Company”), the world’s largest provider of Dialysis Products and Services, has received regulatory approval from Germany’s Federal Institute for Drugs and Medical Devices (Bundesinstitut fur Arzneimittel und Medizinprodukte) for a new phosphate binding agent. The drug “OsvaRen” is expected to be introduced to the German market in the second half of 2006. The Company aims at quickly receiving accelerated approval for the new phosphate binding agent in other countries within the European Union using the mutual recognition process. The new phosphate binding agent should be introduced in all European Countries in 2007.
